NEW YORK, November 11, 2016 /PRNewswire/ --
The Biotech industry rallied in the final hour of trading on Wednesday, November 09, 2016, as the Nasdaq Biotechnology Index advanced 9%, and was on track for its biggest single-day gain in more than eight years. Ahead of today's trading session, Stock-Callers.com looks at Anavex Life Sciences Corp. (NASDAQ: AVXL), Eleven Biotherapeutics Inc. (NASDAQ: EBIO), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), and Tokai Pharmaceuticals Inc. (NASDAQ: TKAI) to see how they have fared at the closing bell yesterday. You can access of our complimentary research reports on these stocks now at:
Anavex Life Sciences
New York-based Anavex Life Sciences Corp.'s stock finished Thursday's session at $3.21, declining 0.62%, with a total trading volume of 477,261 shares. Over the last month, the Company's shares have gained 1.26%. The stock is trading above its 50-day moving average by 2.61%. Moreover, shares of Anavex Life Sciences, which engages in the development of drug candidates for the treatment of Alzheimer's disease, other central nervous system diseases, pain, and various cancers, have a Relative Strength Index (RSI) of 55.72.
On October 05th, 2016, Anavex Life Sciences announced collaboration with Ariana Pharma (Cambridge, MA and Paris, France) to use Ariana's proprietary KEM® (Knowledge, Extraction, Management) patient stratification technology to potentially accelerate ANAVEX 2-73's Phase 2/3 Alzheimer's clinical development timelines. KEM® is a comprehensive and FDA-tested clinical data analysis system that enables full exploitation of complex datasets including of smaller numbers of patients. Visit us today and download your complete report on AVXL for free at:
Shares in Cambridge, Massachusetts-based Eleven Biotherapeutics Inc. ended yesterday's session 26.36% higher at $2.78. A total volume of 10.12 million shares was traded, which was above their three months average volume of 1.43 million shares. The stock has surged 24.66% in the past month. Shares of the Company, which engages in the discovery and development of protein therapeutics to treat eye diseases primarily in the US, are trading 41.46% above their 200-day moving average. Moreover, Eleven Biotherapeutics' stock has an RSI of 59.52.
On November 04th, 2016, Eleven Biotherapeutics announced that it will report Q3 2016 financial results on November 14th, 2016. The company's management team will host a conference call and audio webcast at 8:30 a.m. ET on the same day to discuss the financial results and recent business developments. The complimentary research report on EBIO can be accessed at:
On Thursday, New Haven, Connecticut headquartered Achillion Pharmaceuticals Inc.'s stock jumped 5.31%, to close the day at $4.76. A total volume of 3.27 million shares was traded, which was above their three months average volume of 1.77 million shares. The Company's shares are trading 34.71% below their 50-day moving average. Additionally, shares of Achillion Pharmaceuticals, which discovers, develops, and commercializes small molecule drug therapies for infectious diseases and immune system disorders in the US and internationally, have an RSI of 26.84.
On November 03rd, 2016, Achillion reported a net loss of $20.7 million, or $0.15 per share, for Q3 2016 compared to net income of $26.3 million, or $0.19 per share, for Q3 2015. Cash, cash equivalents, marketable securities, and interest receivable as of September 30th, 2016, were $409.5 million. Achillion recognized in Q3 2015 revenue of $33.8 million under the Janssen Agreement, representing a portion of the premium paid by JJDC. No revenue was recognized during Q3 2016.
On November 04th, 2016, research firm Chardan Capital Markets upgraded the Company's stock rating from 'Sell' to 'Neutral', issuing a target price of $5 per share. Register for free on Stock-Callers.com and download the PDF research report on ACHN at:
Shares in Boston, Massachusetts-based Tokai Pharmaceuticals Inc. ended the day 1.90% higher at $1.07, with a total trading volume of 690,552 shares. The stock is trading below its 50-day moving average by 18.19%. Shares of the Company, which focuses on developing and commercializing therapies for prostate cancer and other hormonally-driven diseases, have an RSI of 44.91.
As per notes filed with the SEC on October 12th, 2016, Timothy J. Barberich notified Tokai Pharmaceuticals on October 10th, 2016, of his resignation as a member of the Company's board of directors and the compensation, audit and nominating and corporate governance committees thereof, effective immediately. Mr. Barberich's decision to resign did not result from any disagreement with the Company on any matter relating to the Company's operations, policies, or practices. Get free access to your research report on TKAI at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA